Background: Most of the available therapeutics of oral lichen planus are associated with adverse effects and there is no sufficient evidence to support the effectiveness of these modalities over placebo or over each other. Micronutrients including antioxidants modify the immune system function and are considered promising alternatives in management of OLP with negligible side effects. The current trial assessed the effect of adjunctive use of systemic vitamin E in symptomatic oral lichen planus patients. Methods: This randomized controlled clinical trial includes 30 symptomatic (erosive and atrophic ) oral lichen planus patients in two parallel groups (interventiontopical triamcinolone acetonide adhesive paste and vitamin E, control -topical triamcinolone acetonide adhesive paste and placebo), with allocation ratio 1:1. Outcome measures were pain intensity, clinical improvement and salivary level of total antioxidant capacity. Results: Mean amount of pain reduction and clinical improvement were greater in the experimental group with statistically significant difference. Mean amount of total antioxidant capacity upregulation was greater in the control group with no statistical difference. Conclusion: Adjunctive use of systemic vitamin E has shown promising results in management of OLP with no side effects.
The fertilizing and nematicidal effects of three organic amendments were evaluated in a pot experiment on melon plants infested by the root-knot nematode Meloidogyne incognita. A soil artificially infested with 4 eggs and juveniles/ ml soil of the nematode was amended with: a) virgin olive pomace (VOP); b) composted olive pomace (COP); c) chicken manure based fertilizer (CM) and d) chicken manure based fertilizer combined with the biological control agent Paecilomyces lilacinus strain 251, brand name BioAct WG (CMB). VOP was applied at doses of 11 (VOP-A), 22 (VOP-B) and 44 t/ha (VOP-C); COP at 4.5 (COP-A), 9 (COP-B) and 18 t/ha (COP-C); CM at 3 t/ha and CMB at 3 t/ha combined with 4 kg/ha of BioAct WG. Untreated soil was used as control. The treatments CM, CMB, VOP-B and COP-B were established on the basis of N requirement of melon plants (120 kg/ha) taking into account soil and amendments N availability. Two weeks later amendment application and nematode inoculation, the soil was poured in 4.8 l clay pots which were arranged in a greenhouse according to a randomized block design with ten replications for each treatment. A one-month old melon seedling (cv. Galia) was transplanted in each pot and organic farming management practices were used during the growing period. At the end of the experiment, 60 days after transplant, plants were uprooted and height, fresh and dry shoot and root weights were recorded. Root gall index, on the roots, caused by the nematode attack, was estimated according to a 0–5 scale. Final nematode population density and reproduction rate were also calculated for each pot. All data were subjected to statistical analysis of variance (ANOVA) and means compared according to Least Significant Difference’s Test. Nematode population and root infestation were significantly suppressed by the addition of all amendments, compared to untreated control. However, CM and CMB resulted in a total more suppressive effect and in a significantly higher plant growth in comparison to all the other treatments. A significant correlation was found between root gall index and eggs and juveniles/g root and final nematode population density. No signifycant correlations were found between nematological parameters or plant growth parameters and amendment doses.
Background A growing number of studies has investigated IL-17 in OLP. However, its exact role and interactions are not fully determined. In addition, the literature investigating its salivary expression is limited. The scarcity in the literature studying lncRNAs was noticed, particularly with regards to correlating them with cytokines in OLP. In the current study, the salivary expression of lncRNA DQ786243 and IL-17 was assessed among different forms of OLP. Methods The study included 52 participants in four equal groups: reticular OLP, erythematous OLP, ulcerative OLP, and control group. All eligible OLP patients underwent conventional oral examination, along with basic charting of their demographic data, pain intensity using a visual analogue scale, and clinical evaluation using the Thongprasom et al. scale. The salivary expression of lncRNA DQ786243 and IL-17 was evaluated for all participants using qRT-PCR. Unstimulated whole saliva samples were used. Data were analyzed for statistical significance. Results No statistically significant difference was observed when comparing the mean age and gender distribution of the studied groups. A statistically significant difference was detected when comparing pain and clinical scores in the three OLP forms. The highest expression of both salivary biomarkers was noticed in ulcerative OLP, followed by erythematous OLP and reticular OLP, then the controls, with a significant difference between the studied groups. Upon comparing the salivary expression of DQ786243 in ulcerative and erythematous OLP, no significant difference was detected. No significant difference was detected when comparing salivary expression of IL-17 in erythematous OLP to the other OLP forms. Conclusions The salivary expression of lncRNA DQ786243 and IL-17 was upregulated in OLP compared to healthy individuals. Besides, their expression increased when the severity of OLP was at its highest level in ulcerative OLP. There was a positive correlation between DQ786243 and IL-17. Trial registration The protocol was registered at ClinicalTrials.gov (NCT04503824). The date of registration is 07/08/2020.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.